Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Electrocardiographic changes after adriamycin chemotherapy.

M K Ali, A Soto, D Maroongroge

    Cancer
    |February 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.

    bioRxiv : the preprint server for biology·2024
    Same author

    Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.

    BMC cancer·2022
    Same author

    Hyper-Reflective Outer Nuclear Layer (HONL) in Vogt-Koyanagi-Harada Disease and Sympathetic Ophthalmia.

    Ocular immunology and inflammation·2022
    Same author

    Equilibria and correlation of systems involving 1-hexyl-3-methylpyridinium trifluoromethanesulfonate.

    RSC advances·2022
    Same author

    The interaction of deep convection with the general circulation in Titan's atmosphere. Part 1: Cloud Resolving Simulations.

    Icarus·2021
    Same author

    [Prevalence and incidence of ictus in Europe: systematic review and meta-analysis].

    Anales del sistema sanitario de Navarra·2021

    Adriamycin (Doxorubicin) chemotherapy can decrease QRS voltage, indicating potential cardiomyopathy. This ECG change is less reliable for predicting early toxicity in patients with congestive heart failure or pleural effusion.

    Area of Science:

    • Cardiology
    • Oncology
    • Pharmacology

    Background:

    • Adriamycin (Doxorubicin) is a key chemotherapy agent for metastatic breast cancer.
    • Electrocardiographic (ECG) changes, particularly QRS voltage, are monitored during Adriamycin treatment.
    • Cardiomyopathy is a known side effect of Adriamycin therapy.

    Purpose of the Study:

    • To evaluate electrocardiographic (ECG) changes, specifically QRS voltage, in patients receiving Adriamycin (Doxorubicin) chemotherapy.
    • To assess the utility of QRS voltage changes in predicting Adriamycin-induced cardiomyopathy and congestive heart failure (CHF).
    • To investigate the influence of pleural effusion on ECG findings during Adriamycin treatment.

    Main Methods:

    • Retrospective review of electrocardiograms (ECGs) from 146 patients with metastatic breast cancer.

    Related Experiment Videos

  • ECGs were analyzed before, during, and after Adriamycin (Doxorubicin) chemotherapy.
  • Correlation of QRS voltage changes with the development of cardiomyopathy, CHF, and pleural effusion.

    • Main Results:

    • A significant decrease in QRS voltage was observed in patients who developed Adriamycin-induced cardiomyopathy.
    • The decrease in QRS voltage was more pronounced at the onset of congestive heart failure (CHF) than at the conclusion of chemotherapy.
    • An inverse relationship was noted between the extent of pleural effusion and QRS voltage amplitude in patients without CHF.

    Conclusions:

    • Sudden, severe decreases in QRS voltage at the onset of CHF limit its value for predicting early Adriamycin toxicity.
    • Caution is advised when interpreting QRS voltage changes in patients with significant pleural effusion due to potential confounding effects.
    • Monitoring QRS voltage remains important, but its interpretation requires consideration of concurrent clinical conditions like CHF and pleural effusion.